Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $158

Benzinga Newsdesk www.benzinga.com Positive 78.1%

Neg 0% Neu 0% Pos 78.1%

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $150 to $158.